SRF’s Q2FY23 print was mixed with chemicals business EBITDA holding up QoQ in aseasonally weak quarter (up 2x YoY). Ref-gas and specialty business outperformedour expectations and the management expects specialty segment revenue growth inFY23 to exceed the guidance of >20%.